Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
68°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc
(NQ:
XENE
)
42.94
+1.04 (+2.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Earnings Scheduled For May 9, 2023
May 09, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
Via
Benzinga
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
May 03, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Where Xenon Pharmaceuticals Stands With Analysts
April 25, 2023
Via
Benzinga
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Xenon Pharmaceuticals Earnings Preview
February 28, 2023
Via
Benzinga
The Latest Analyst Ratings for Xenon Pharmaceuticals
January 31, 2023
Via
Benzinga
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
May 02, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
April 25, 2023
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
April 25, 2023
Via
Benzinga
Analyst Ratings for Xenon Pharmaceuticals
December 14, 2022
Via
Benzinga
Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed
December 06, 2022
Via
Benzinga
Where Xenon Pharmaceuticals Stands With Analysts
November 28, 2022
Via
Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, April 25, 2023: GM, SNAP, WEN, XENE, CXAI
April 25, 2023
General Motors (GM) - Shares traded about 3% higher Tuesday morning following better-than-expected Q1 earnings and sales and raised guidance. The company said global deliveries of its automobiles
Via
Benzinga
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 24, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 21, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 18, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
March 22, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 01, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
February 22, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 08, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Applied UV (NASDAQ: AUVI) Effectively Doubles Its Size Following A Merger That Could Help Shape The Industry – A Brief Look At The Company
February 02, 2023
A recent merger between Applied UV Inc. (NASDAQ: AUVI), Puro Lighting (PURO), and LED Supply Co. (LED Supply) seems to have triggered some excitement in the ultraviolet (UV) disinfection equipment...
Via
Benzinga
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
January 09, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
December 12, 2022
Via
Benzinga
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
December 02, 2022
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
November 30, 2022
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
November 29, 2022
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022
November 28, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.